Authorized purpose: Automatically label and volumetrically quantify segmentable brain structures and white matter hyperintensities (WMH) from MR images in adults and adolescents aged 18 years and older, as a support tool for properly trained clinicians assessing structural MRIs; patient-management decisions must not rely solely on the device results.
Clinical role
Automated structural-brain MRI segmentation, volumetric quantification, and WMH analysis with clinician review as a support tool; sequence compatibility is checked before analysis and results can be reviewed longitudinally.
Images and patients
MRI · Brain
Key limitation
Keep in mind: The software is a support tool and patient-management decisions must not be based solely on its results. The FDA scope is limited to segmentable brain structures and WMH from the specified T1 and T2 FLAIR MRI inputs; WMH performance varies materially by lesion burden, and the packet does not establish a general diagnostic claim or a specific current PACS, RIS, EHR, or deployment configuration.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Automatically label and volumetrically quantify segmentable brain structures and white matter hyperintensities (WMH) from MR images in adults and adolescents aged 18 years and older, as a support tool for properly trained clinicians assessing structural MRIs; patient-management decisions must not rely solely on the device results.
Which images or clinical context are in scope?Modality: MRI Anatomy or clinical context: Brain Input: DICOM-compatible MR images, including 3D T1-weighted Gradient Echo structural MRI for brain structures and T2 FLAIR MRI for WMH identification, from adults and adolescents aged 18 years and older; the application checks available sequences for compatibility before launching analysis.
Who uses it?Intended users: Clinicians with proper training
What does the software produce?Output: Volumes for gray matter, white matter, cerebrospinal fluid, and intracranial volume, plus WMH quantification, segmentation color overlays, morphometric reports, comparisons with age- and gender-matched normative percentile data when available, longitudinal reporting, and DICOM-formatted results displayable on DICOM workstations and PACS.
What is its most important limitation?Key limitation: The software is a support tool and patient-management decisions must not be based solely on its results. The FDA scope is limited to segmentable brain structures and WMH from the specified T1 and T2 FLAIR MRI inputs; WMH performance varies materially by lesion burden, and the packet does not establish a general diagnostic claim or a specific current PACS, RIS, EHR, or deployment configuration.
Clinical takeaway. Clinical role: Automatically label and volumetrically quantify segmentable brain structures and white matter hyperintensities (WMH) from MR images in adults and adolescents aged 18 years and older, as a support tool for properly trained clinicians assessing structural MRIs; patient-management decisions must not rely solely on the device results.
Evidence takeaway. Evidence from the reviewed source record: FDA K232231 reports software verification and validation against manual expert segmentation. For T1 brain structures, Dice scores and relative-volume differences were GM 0.983 and 2.846, WM 0.990 and 1.643, CSF 0.955 and 7.495, and ICV 0.994 and 0.496. For T2 FLAIR WMH, burden-stratified Dice scores were 0.506, 0.636, 0.774, and 0.885 for low, medium, high, and very high WMH, with corresponding absolute volume errors of 0.675, 2.544, 3.097, and 7.833 mL; the packet also reports Pearson correlation of 0.88 for WMH count. No sample size or clinical-outcome study is stated in the reviewed FDA packet.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Automatically label and volumetrically quantify segmentable brain structures and white matter hyperintensities (WMH) from MR images in adults and adolescents aged 18 years and older, as a support tool for properly trained clinicians assessing structural MRIs; patient-management decisions must not rely solely on the device results.
Automated structural-brain MRI segmentation, volumetric quantification, and WMH analysis with clinician review as a support tool; sequence compatibility is checked before analysis and results can be reviewed longitudinally.
DICOM-compatible MR images, including 3D T1-weighted Gradient Echo structural MRI for brain structures and T2 FLAIR MRI for WMH identification, from adults and adolescents aged 18 years and older; the application checks available sequences for compatibility before launching analysis.
Volumes for gray matter, white matter, cerebrospinal fluid, and intracranial volume, plus WMH quantification, segmentation color overlays, morphometric reports, comparisons with age- and gender-matched normative percentile data when available, longitudinal reporting, and DICOM-formatted results displayable on DICOM workstations and PACS.
The software is a support tool and patient-management decisions must not be based solely on its results. The FDA scope is limited to segmentable brain structures and WMH from the specified T1 and T2 FLAIR MRI inputs; WMH performance varies materially by lesion burden, and the packet does not establish a general diagnostic claim or a specific current PACS, RIS, EHR, or deployment configuration.
FDA K232231 reports software verification and validation against manual expert segmentation. For T1 brain structures, Dice scores and relative-volume differences were GM 0.983 and 2.846, WM 0.990 and 1.643, CSF 0.955 and 7.495, and ICV 0.994 and 0.496. For T2 FLAIR WMH, burden-stratified Dice scores were 0.506, 0.636, 0.774, and 0.885 for low, medium, high, and very high WMH, with corresponding absolute volume errors of 0.675, 2.544, 3.097, and 7.833 mL; the packet also reports Pearson correlation of 0.88 for WMH count. No sample size or clinical-outcome study is stated in the reviewed FDA packet.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
FDA K232231 reports software verification and validation against manual expert segmentation. For T1 brain structures, Dice scores and relative-volume differences were GM 0.983 and 2.846, WM 0.990 and 1.643, CSF 0.955 and 7.495, and ICV 0.994 and 0.496. For T2 FLAIR WMH, burden-stratified Dice scores were 0.506, 0.636, 0.774, and 0.885 for low, medium, high, and very high WMH, with corresponding absolute volume errors of 0.675, 2.544, 3.097, and 7.833 mL; the packet also reports Pearson correlation of 0.88 for WMH count. No sample size or clinical-outcome study is stated in the reviewed FDA packet.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
QP-Brain® regulatory performance study summary
DesignStand-Alone Performance
PopulationAdult
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K232231
IndependenceIndependence not established
K232231
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K232231. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: DICOM-compatible MR images, including 3D T1-weighted Gradient Echo structural MRI for brain structures and T2 FLAIR MRI for WMH identification, from adults and adolescents aged 18 years and older; the application checks available sequences for compatibility before launching analysis.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: DICOM-compatible input and return/display of outputs on third-party DICOM workstations and PACS are described. Exact DICOM objects, interfaces, versions, routing, and current local compatibility are not established by the FDA packet.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes QP-Brain as software that operates on off-the-shelf hardware from multiple vendors. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "and operate on off-the-self hardware (multiple vendors).". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Volumes for gray matter, white matter, cerebrospinal fluid, and intracranial volume, plus WMH quantification, segmentation color overlays, morphometric reports, comparisons with age- and gender-matched normative percentile data when available, longitudinal reporting, and DICOM-formatted results displayable on DICOM workstations and PACS.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Volumes for gray matter, white matter, cerebrospinal fluid, and intracranial volume, plus WMH quantification, segmentation color overlays, morphometric reports, comparisons with age- and gender-matched normative percentile data when available, longitudinal reporting, and DICOM-formatted results displayable on DICOM workstations and PACS.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes QP-Brain as software that operates on off-the-shelf hardware from multiple vendors. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "and operate on off-the-self hardware (multiple vendors).". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
DICOM-compatible input and return/display of outputs on third-party DICOM workstations and PACS are described. Exact DICOM objects, interfaces, versions, routing, and current local compatibility are not established by the FDA packet.
Quibim's security and privacy statement describes an ISO 27001-certified information security management system and ISO 13485-certified quality management system; QP-Care platform data hosted on Microsoft Azure protected by multi-factor authentication and encryption in transit and at rest; pseudonymization of processed data; regular penetration tests following OSSTMM and OWASP methodologies; staff security training and confidentiality obligations.
Vendor-wide
Checked 2026-10-27
Vendor statement; certificates were not read. Applicant name variants ('QUIBIM S.L.', 'Quibim S.L.') are bridged via the identical distinctive name and QP product naming. Exact-release scope is not established.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
23Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission
No public price or quote for the exact K232231 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-08 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: ANDI 2.2 processes brain MR images for atlas-assisted visualization, segmentation and volumetric quantification, presenting adjunctive DICOM-readable information for trained medical professionals; it does not predict, diagnose or interpret brain health.
Authorized purpose: Morph automatically labels, visualizes, and volumetrically quantifies segmentable brain structures from MR images and may compare measurements with reference percentile data; it is adjunctive and not the sole basis for final decisions.
Authorized purpose: Brain MRI morphometry and white matter hyperintensity quantification, including normative comparison and longitudinal change assessment for clinician review.
Authorized purpose: Adjunctive quantitative brain MRI analysis that compares patient measures with normative and longitudinal references; a physician reviews all results and makes the clinical decision.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.